Karnataka DC Launches Real-Time Database For Tapentadol Stocks To Curb Misuse

Bengaluru: The database enables enforcement officers, who must update the portal after collecting stock data from drug distributors every day, tally the demand and supply numbers between wholesalers and retailers and take immediate action if the numbers do not add up, noted Dr Umesh S, State Drugs Controller.

“Until now, we did not have a track of the quantum of the drugs being supplied from wholesalers to retailers. We are doing this so that the daily updated figures might also make chemists think twice before enabling any misuse,” he told DH.

Licence holders can also directly upload their stock details using their firm ID.

“We are monitoring this real time to control the supply of this drug because it is the most-misused among the narcotic drugs and psychotropic substances. At the end of the day, if we are suspecting any distributors, we can cross-check their details and catch them in the act,” a senior official from the department said.

Dr Arun Kandasamy, Psychiatry Professor and Chief, Centre for Addiction Medicine, Nimhans, explained that although Tapentadol is an oral drug, people who overuse the drug administer it to themselves via injections to obtain a high.

“In our 80-bed facility, about 50% of the admissions are of people with Tapentadol addiction. Almost 70% to 80% of them also test positive for Hepatitis C infection as they might be sharing the syringes or containers with the crushed tablets. Many are also first-time drug users and most are aged between 15 and 30 years who access it via the black market,” he said.

The move to track sales will control how much of the drug is made available, potentially discouraging new users and reducing addiction risks, he noted.

Dr Shivanna Venkataramana, senior anaesthesiologist, noted that this drug is also being used for chronic pain conditions in India, but should be used as a second line of treatment in these conditions and only on doctor’s Prescription.

“To my knowledge, there is no strict regulation of this drug in India, so this move (to track its stocks) might help curb some misuse,” he said.

Related Posts

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026. India is witnessing a growing…

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?